Sunday, 15 November 2026European Markets

ERAMET And DSM KON Have A High Dividend Yield And Return On Equity In The Basic Materials Sector.

Automated market report from our archive (2020–2024), published before source-traceability. How we work

Loading stream...

(vianews) - eramet (era.pa) is among this list of stock assets with the highest dividend rate and return on equity on the basic materials sector.

financial asset price forward dividend yield return on equity
eramet (era.pa) €89.50 3.94% 51.96%
dsm kon (dsm.as) €114.40 2.29% 4.69%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. eramet (era.pa)

3.94% forward dividend yield and 51.96% return on equity

eramet s.a. operates as a mining and metallurgical company in france, asia, europe, north america, and internationally. the company extracts and processes manganese ore and nickel ore; and extracts and develops mineral sands. it also produces ferronickel, nickel pig iron, briquettes, nickel salts, high purity nickel, nickel ferroalloys, and alloy steel and casting; manganese alloys, such as high-carbon ferromanganese, silicomanganese, low and medium-carbon ferromanganese, and low-carbon silicomanganese for use in batteries, pigments, construction, and automotive industries; and mineral sands, such as titanium dioxide, high-purity pig iron, zircon, and ilmenite used in ceramics and pigments. in addition, it operates moanda mine in gabon; nickel mines in new caledonia and indonesia; and mineral sand mine in senegal and argentina. eramet s.a. was incorporated in 1880 and is headquartered in paris, france.

earnings per share

as for profitability, eramet has a trailing twelve months eps of €31.

pe ratio

eramet has a trailing twelve months price to earnings ratio of 2.89. meaning, the purchaser of the share is investing €2.89 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 51.96%.

dividend yield

as claimed by morningstar, inc., the next dividend payment is on jun 3, 2022, the estimated forward annual dividend rate is 3.5 and the estimated forward annual dividend yield is 3.94%.

revenue growth

year-on-year quarterly revenue growth grew by 10.3%, now sitting on 5.1b for the twelve trailing months.

more news about eramet.

2. dsm kon (dsm.as)

2.29% forward dividend yield and 4.69% return on equity

koninklijke dsm n.v., a science-based company, engages in health and nutrition businesses in the netherlands, switzerland, rest of europe, north america, latin america, china, rest of asia, and internationally. it operates through animal nutrition & health (anh); health, nutrition & care (hnc); and food & beverage segments. the animal nutrition & health segment offers essential products, including vitamins, premixes, and carotenoids; performance solutions, such as enzymes, microbes, and eubiotics; precision services comprising support with data analysis to measure animal health and environmental footprint on farm level and feed safety; and methane reducing feed additive for ruminants. the health, nutrition & care segment provides solutions for the early life nutrition, dietary supplement, pharmaceutical, medical nutrition, personal care and aroma, and biomedical materials markets. it offers vitamins, nutritional lipids, minerals, carotenoids, nutraceuticals, digestive enzymes, probiotics and prebiotics, active pharmaceutical ingredients, and sunscreen filters, as well as a range of biomedical solutions; premix, market-ready solutions, and personalized nutrition solutions; and regulatory affairs and formulation expertise, and customized solutions. the food & beverage segment provides ingredients and solutions for use in a range of food products, such as dairy; bakery, cereals, and bars; savory foods; beverages and brewing; confectionery and fruit; plant-based meat and fish alternatives; and petfood. the company was founded in 1902 and is headquartered in heerlen, the netherlands.

earnings per share

as for profitability, dsm kon has a trailing twelve months eps of €6.26.

pe ratio

dsm kon has a trailing twelve months price to earnings ratio of 18.27. meaning, the purchaser of the share is investing €18.27 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 4.69%.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, dsm kon's stock is considered to be overbought (>=80).

dividend yield

as claimed by morningstar, inc., the next dividend payment is on aug 4, 2022, the estimated forward annual dividend rate is 2.63 and the estimated forward annual dividend yield is 2.29%.

more news about dsm kon.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Late-2026 Biotech Catalyst Season: FDA Decisions and Pivotal Readouts Converge Across Oncology, Hepatology and Cardiometabolic
Mid-November 2026 is dense with scheduled biotech catalysts. The ivonescimab BLA PDUFA date is 2026-11-14, the lorundrostat PDUFA date is 2026-12-22, and Phase 3 ECLIPSE hepatitis delta data are due in Q1 2027. Alongside these, siRNA and antibody programs (plozasiran, elebsiran/tobevibart, ianalumab, nipocalimab) reported or presented data at AHA, AASLD, ACR and ASH, while Oryzon advanced iadademstat in AML with Spanish trial authorizations and a planned ALICE-3 Phase III. Late-stage data and regulatory milestones are driving the sentiment. A planned delisting (EGM 2026-11-19, application 2027-01-25) is a separate corporate-structure event with no clear link to the rest.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,580 source documents archived
Query this data → isubstrate.com